Talk:Ethyl eicosapentaenoic acid

From WikiProjectMed
Jump to navigation Jump to search

Additional information

edit In the section on Cardiovascular diseases, diabetes following the first paragraph on the JELIS trial (ending with the phrase "...apparently through mechanisms independent from regulation of lipid metabolism") please add:

E-EPA has been approved by the FDA as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with very high triglycerides (VHTG) or severe hypertriglyceridemia, defined as TG ≥500 mg/dL.[1] When used to reduce very high triglycerides, the FDA-approved prescription E-EPA-only omega-3 fatty acid product was not associated with increases in LDL-C as compared to placebo in a clinical trial.[2] Prescription and supplement omega-3 fatty acid mixtures that contain docosahexaenoic acid (DHA) may elevate LDL-C.[3]

In the next paragraph, after the sentence ending "... and its cardiovascular complications, such as coronary artery disease and thickening of carotid arteries." please add the following sentences:

E-EPA has been shown to benefit endothelial function[4] and lipid peroxidation in humans[5], both of which are associated with atherosclerosis. Due to its potent antioxidant effects, E-EPA uniquely reduces lipoprotein oxidation in-vitro.[6][7][8] Further, improvements in endothelial function, represented by changes in nitric oxide (NO) release, alone and in combination with statin, have been observed with E-EPA.[9][10] When tested in vitro in model membrane lipid vesicles, EPA, but not other TG-lowering agents tested in this model, inhibited the formation of cholesterol crystalline domains associated with atherosclerosis.[11]

References

  1. ^ Weintraub, HS (2014). "Overview of prescription omega-3 fatty acid products for hypertriglyceridemia". Postgrad Med. 126: 7–18. doi:10.3810/pgm.2014.11.2828. PMID 25387209. Retrieved 20 April 2015.
  2. ^ Bays, HE; Ballantyne, CM; Kastelein, JJ; Isaacsohn, JL; Braeckman, RA; Soni, PN (2011). "Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)". Am J Cardiol. 108: 682–690. doi:10.1016/j.amjcard.2011.04.015. PMID 21683321. {{cite journal}}: |access-date= requires |url= (help)
  3. ^ Jacobson, TA; Ito, MK; Macki, KC (2014). "National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary". J Clin Lipidol. 8: 473–488. doi:10.1016/j.jacl.2014.07.007. PMID 25234560.
  4. ^ Kohashi, K; Nakagomi, A; Saiki, Y (2015). "Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia". Journal of Atherosclerosis and Thrombosis. 21 (7): 12–29. doi:10.5551/jat.21022. PMID 24670266. Retrieved 20 April 2015.
  5. ^ Kelley, NS; Yoshida, Y; Erickson, KL (2014). "Do n-3 polyunsaturated fatty acids increase or decrease lipid peroxidation in humans?". 12 (8): 403–415. doi:10.1089/met.2014.0045. PMID 25045922. {{cite journal}}: |access-date= requires |url= (help); Cite journal requires |journal= (help)
  6. ^ Mason, RP; Jacob, R; Beauregard, G; Rowe, J (2011). "Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]". J Clin Lipidol. 5: 201.
  7. ^ Mason, RP; Jacob, R; Corbalan, JJ; Malinski, T (2015). "Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract]". J Am Coll Cardiol. 65: A2139.
  8. ^ Mason, RP; Jacob, RF (2015). "Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism". Biochim Biophys Acta. 1842 (2): 502–509. doi:10.1016/j.bbamem.2014.10.016. PMID 25449996. Retrieved 20 April 2015.
  9. ^ Mason, RP; Jacob, R; Beauregard, G; Rowe, J (2011). "Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]". J Clin Lipidol. 5: 201.
  10. ^ Mason, RP; Jacob, RF; Corbalan, J; Malinski, T. "Combination treatment with eicosapentaenoic acid and atorvastatin active metabolite reverses endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. Presented at the Deuel Conference on Lipids, March 3-6, 2015, Monterey, California". {{cite journal}}: Cite journal requires |journal= (help)
  11. ^ Mason, RP; Jacob, RF (2015). "Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism". Biochim Biophys Acta. 1842 (2): 502–509. doi:10.1016/j.bbamem.2014.10.016. PMID 25449996. Retrieved 20 April 2015.

- — Preceding unsigned comment added by 5020QVRoad (talk • contribs) 13:27, 21 April 2015 (UTC)[reply]

article cleanup

Note - this article was not written per the community's standards for article about health - WP:MEDMOS for style and WP:MEDRS for sourcing, and I'm fixing it. There also was a lot of content in here about Eicosapentaenoic acid which is distinct from the subject of this article... and many of the sources were very old, and primary. i will build back up the Research section from recent reviews. Jytdog (talk) 21:13, 31 March 2016 (UTC)[reply]

note on related article discussions

See discussions at Talk:Omega-3 fatty acid about making all these fish oil/omega-3 articles make sense across Wikipedia. Am not going to restore "research" until that gets worked out, as the same content is already in a bunch of different articles. Jytdog (talk) 00:52, 1 April 2016 (UTC)[reply]

Retrieved from "https://mdwiki.org/wiki/Talk:Ethyl_eicosapentaenoic_acid"